• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

模块装置:一种设计由压力定量吸入器产生的气雾剂的方法。

Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers.

作者信息

Ganderton D, Lewis D, Davies R, Meakin B, Brambilla G, Church T

机构信息

Vectura Ltd., Bath, U.K.

出版信息

Respir Med. 2002 Aug;96 Suppl D:S3-8. doi: 10.1016/s0954-6111(02)80018-x.

DOI:10.1016/s0954-6111(02)80018-x
PMID:12201079
Abstract

Although popular, the pressurized metered dose inhaler generates coarse, fast moving clouds so that the fraction reaching the lung is small. These shortcomings can be redressed by Modulite which permutes the following variables: the non-volatile components of a solution formula, the actuator orifice geometry, the volume of the metered solution and the vapour pressure of the propellants. This permits the design of aerosols with chosen particle size and plume speed. This facilitates co-ordination of dose generation with inspiration, reduces oropharyngeal deposition and provides a mechanism for targeting drug delivery to different parts of the lung. These principles are exemplified by designing an HFA-propelled beclometasone dipropionate product which closely matches existing products which use chlorofluorocarbons.

摘要

尽管压力定量吸入器很受欢迎,但它会产生粗大、快速移动的药雾,因此到达肺部的比例很小。Modulite可以弥补这些缺点,它可以改变以下变量:溶液配方中的非挥发性成分、雾化器孔口几何形状、定量溶液的体积和推进剂的蒸气压。这使得能够设计出具有选定粒径和药雾速度的气雾剂。这有助于使剂量产生与吸气相协调,减少口咽沉积,并提供一种将药物输送到肺部不同部位的机制。通过设计一种以氢氟烷烃为推进剂的丙酸倍氯米松产品来举例说明这些原理,该产品与现有的使用氯氟烃的产品非常匹配。

相似文献

1
Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers.模块装置:一种设计由压力定量吸入器产生的气雾剂的方法。
Respir Med. 2002 Aug;96 Suppl D:S3-8. doi: 10.1016/s0954-6111(02)80018-x.
2
Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.Respimat软雾吸入器与压力定量吸入器的气雾剂速度和喷雾持续时间比较。
J Aerosol Med. 2005 Fall;18(3):273-82. doi: 10.1089/jam.2005.18.273.
3
The formulation and evaluation of a CFC-free budesonide pressurised metered dose inhaler.
Respir Med. 2003 Nov;97 Suppl D:S4-9. doi: 10.1016/j.rmed.2003.10.003.
4
Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants.从含有非氯氟烃和氯氟烃推进剂的压力定量吸入器中递送的氟尼缩松的沉积和药代动力学。
J Aerosol Med. 2001 Summer;14(2):197-208. doi: 10.1089/08942680152484126.
5
Developing an in vitro understanding of patient experience with hydrofluoroalkane-metered dose inhalers.建立对患者使用氢氟烷烃定量吸入器体验的体外理解。
J Pharm Sci. 2014 Nov;103(11):3648-3656. doi: 10.1002/jps.24167. Epub 2014 Sep 16.
6
Computational analyses of a pressurized metered dose inhaler and a new drug-aerosol targeting methodology.定量压力气雾剂及新型药物气溶胶靶向给药方法的计算分析
J Aerosol Med. 2007 Fall;20(3):294-309. doi: 10.1089/jam.2006.0617.
7
Plume Characteristics of Two HFA-Driven Inhaled Corticosteroid/Long-Acting Beta2-Agonist Combination Pressurized Metered-Dose Inhalers.两种氢氟烷烃驱动的吸入性皮质类固醇/长效β2受体激动剂联合定量气雾剂的羽流特征
Adv Ther. 2015 Jun;32(6):567-79. doi: 10.1007/s12325-015-0219-z. Epub 2015 Jun 23.
8
Spray pattern analysis for metered dose inhalers I: Orifice size, particle size, and droplet motion correlations.定量吸入器的喷雾模式分析I:喷孔尺寸、颗粒大小及液滴运动相关性
Drug Dev Ind Pharm. 2006 Oct;32(9):1033-41. doi: 10.1080/03639040600637598.
9
Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica.沙丁胺醇氯氟烃和氢氟烷烃-134a制剂在人体气道模型中的呼吸道沉积模式。
J Aerosol Med. 2001 Summer;14(2):255-66. doi: 10.1089/08942680152484180.
10
Metered-dose inhaler formulations with beclomethasone-17,21-dipropionate using the ozone friendly propellant R 134a.使用对臭氧层友好的推进剂R 134a的倍氯米松-17,21-二丙酸酯定量吸入气雾剂制剂。
Eur J Pharm Biopharm. 1998 Jul;46(1):77-83. doi: 10.1016/s0939-6411(97)00115-x.

引用本文的文献

1
Comparison of Formoterol, Glycopyrrolate, and Beclomethasone Dipropionate Pharmacokinetic Profile after Inhaled Administration as pMDI Using HFA134a or HFA152a Propellant: Preclinical Assessment of Drug Exposure in Sprague-Dawley Rat Model.使用HFA134a或HFA152a推进剂以压力定量吸入气雾剂(pMDI)吸入给药后福莫特罗、格隆溴铵和丙酸倍氯米松药代动力学特征的比较:在Sprague-Dawley大鼠模型中对药物暴露的临床前评估
J Aerosol Med Pulm Drug Deliv. 2025 Feb;38(1):18-25. doi: 10.1089/jamp.2024.0019. Epub 2024 Sep 26.
2
How to engineer aerosol particle properties and biopharmaceutical performance of propellant inhalers.如何设计推进剂吸入器的气溶胶颗粒性质和生物制药性能。
Int J Pharm. 2023 Mar 5;634:122676. doi: 10.1016/j.ijpharm.2023.122676. Epub 2023 Feb 3.
3
Extrafine HFA-beclomethasone-formoterol vs. nonextrafine combination of an inhaled corticosteroid and a long acting β2-agonist in patients with persistent asthma: A systematic review and meta-analysis.精计量 HFA 布地奈德福莫特罗对比持续哮喘患者中吸入性皮质激素和长效β2-激动剂的非精计量联合治疗:系统评价和荟萃分析。
PLoS One. 2021 Sep 3;16(9):e0257075. doi: 10.1371/journal.pone.0257075. eCollection 2021.
4
Water Uptake by Evaporating pMDI Aerosol Prior to Inhalation Affects Both Regional and Total Deposition in the Respiratory System.吸入前蒸发的定量吸入气雾剂(pMDI)的水分摄取会影响呼吸系统中的局部和总沉积。
Pharmaceutics. 2021 Jun 24;13(7):941. doi: 10.3390/pharmaceutics13070941.
5
Impact of extrafine formulations of inhaled corticosteroids/long-acting beta-2 agonist combinations on patient-related outcomes in asthma and COPD.吸入性皮质类固醇/长效β2受体激动剂复方超细制剂对哮喘和慢性阻塞性肺疾病患者相关结局的影响。
Patient Relat Outcome Meas. 2014 Nov 27;5:153-62. doi: 10.2147/PROM.S55276. eCollection 2014.
6
The challenge of delivering therapeutic aerosols to asthma patients.向哮喘患者输送治疗性气雾剂的挑战。
ISRN Allergy. 2013 Aug 5;2013:102418. doi: 10.1155/2013/102418. eCollection 2013.
7
Lung penetration and patient adherence considerations in the management of asthma: role of extra-fine formulations.在哮喘管理中考虑肺部渗透和患者依从性:超细制剂的作用。
J Asthma Allergy. 2013;6:11-21. doi: 10.2147/JAA.S14743. Epub 2013 Jan 9.
8
Urinary pharmacokinetic methodology to determine the relative lung bioavailability of inhaled beclometasone dipropionate.尿药动力学方法测定吸入用丙酸倍氯米松的相对肺生物利用度。
Br J Clin Pharmacol. 2012 Sep;74(3):456-64. doi: 10.1111/j.1365-2125.2012.04210.x.
9
Effect of AeroChamber Plus™ on the lung and systemic bioavailability of beclometasone dipropionate/formoterol pMDI.AeroChamber Plus™ 对丙酸倍氯米松/福莫特罗 pMDI 的肺部和全身生物利用度的影响。
Br J Clin Pharmacol. 2011 Dec;72(6):932-9. doi: 10.1111/j.1365-2125.2011.04024.x.
10
Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler.丙酸倍氯米松/福莫特罗:装于氢氟烷烃驱动的压力定量吸入器中。
Drugs. 2006;66(11):1475-83; discussion 1484-5. doi: 10.2165/00003495-200666110-00005.